


AMLS CRE/ESBL Survey

2/12/2011



25 Labs responded

Does your Lab Screen for CRE

- 80% yes 20% NO (25 responses)
- National method (TSB with McConk and Mero disc etc) = 12
- CDC Method = 4
- Chromagar CRE = 3

What patient populations does your hospital screen for CRE?

Answer Options	Response Percent	Response Count
Hospital transfers (eg from hospitals with confirmed ICU patients)	86.4%	19
Patients from countries with high incidence	27.3%	6
Does not apply (do not screen)	72.7%	16
Other patients	9.1%	2
Other (please specify)	27.3%	6
		10
	<i>answered question</i>	22
	<i>skipped question</i>	3

What Method does your Laboratory use to confirm suspect CRE (more than one choice is allowed)?

Answer Options	Response Percent	Response Count
Etest	70.8%	17
Modified Hodge plate	45.8%	11
Synergy test	37.5%	9
Molecular test	8.3%	2
Send to reference lab	70.8%	17
Other	0.0%	0
Other (please specify)		7
<i>answered question</i>		24
<i>skipped question</i>		1

E test/Modified Hodge Combo= 18

E test/Modified Hodge/Synergy= 8

Does your Laboratory screen for ESBL		
Answer Options	Response Percent	Response Count
Yes	52.0%	13
No	48.0%	12
If yes describe the method (e.g. Chromagar)		15
<i>answered question</i>		25
<i>skipped question</i>		0

Chromagar=4

Automated methods=3

Screening discs = eg Cefpodoxime /
Clav acid

How Does your Laboratory Confirm ESBL presence?		
Answer Options	Response Percent	Response Count
Automated instrument	52.0%	13
Etest	28.0%	7
Phenotypically (e.g. Double disc)	76.0%	19
No Confirmation	0.0%	0
Other	0.0%	0
If other please describe		3
	<i>answered question</i>	25
	<i>skipped question</i>	0

Automated Instrument and Phenotypically = Most common combination

If your laboratory has implemented or is about to implement EUCAST do you propose to continue to confirm ESBL presence by a second method?

Answer Options	Response Percent	Response Count
Yes	56.0%	14
No	12.0%	3
Dont know yet	24.0%	6
Does not apply	8.0%	2
<i>answered question</i>		25
<i>skipped question</i>		0

What screening breakpoints (MIC and/or zone diameter) does your Laboratory use for surveillance of carbapenemase production? (Leave textboxes blank if they do not apply)

Answer Options	Response Percent	Response Count
Ertapenem MIC	59.1%	13
Imipenem MIC	22.7%	5
Meropenem MIC	86.4%	19
Ertapenem ZD	13.6%	3
Imipenem ZD	9.1%	2
Meropenem ZD	59.1%	13
	<i>answered question</i>	22
	<i>skipped question</i>	3

Quite a variety of Breakpoints supplied – some guidance required.